Vera Therapeutics is expected to report a Q2 2026 loss of $1.60 per share on zero revenue, while the stock currently trades at $32.02 against an average analyst target of $84.58.
Investors are primarily focused on the commercial launch execution of Trutakna (atacicept) following its FDA accelerated approval on July 7, 2026.
Although the reporting period ended prior to the approval, management commentary on physician engagement and the upcoming Q3 2026 confirmatory eGFR data from the ORIGIN 3 trial will be critical. The company continues to invest heavily in its immunology pipeline, resulting in a significantly wider year-over-year loss as it transitions to a commercial-stage entity.